

References

1. **Abbas and Lichtman A.H. (2009)** : "Ch.2 Innate Immunity". Basic Immunology. Functions and disorders of the immune system (3rd ed.).
2. **Abbas and Lichtman A.H. (2009)** : Basic immunology-Chapter one 3rd ed , introduction to immune system pp 1-23.
3. **Abbas and Lichtman A.H. (2009)** : Basic immunology-Chapter three 3rd ed , function and disorders of the immune system, pp 45-67.
4. **Adamantiades (1930)** : Hulusi Behçet Medical Society of Athens; 586-93.
5. **Adams A and Lehman TJ (2005)** : Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Curr Opin Rheumatol. Sep; 17 (5): 612-6.
6. **Aderem A. and Ulevitch R.J (2000)** : Nature 406: 782.
7. **Aderem Alan, Underhill and David (1999)** : "Mechanisms of Phagocytosis in Macrophages". Annual Review of Immunology 17: 593–623.
8. **Adler A.J. et al., (1998)** : J. Exp. Med. 187:1555.
9. **Admou B (2009)** : Ann Biol Clin (Paris). May-Jun.
10. **Agata Y. et al., (1996)** : Int. Immunol. 8:765.
11. **Aglas F, Hermann J, and Egger G (1998)** : Abnormal directed migration of blood polymorphonuclear leukocytes in rheumatoid arthritis. Potential role in increased susceptibility to bacterial infections. Mediators Inflamm, 7:19-23.
12. **Aicher A. et al., (2000)** : J. Immunol. 164:4689.
13. **Ainsworth and Claire (2003)** : The stranger within (subscription). "New Scientist", Nov. 15, 356 (6): 580–92.
14. **Ainsworth and Claire (2003)** : "pregnancy may induce autoimmunity" Nature Reviews Immunology; 6 (5): 394–403.

15. **Akiko Iwasaki and Ruslan Medzhitov (2010)** : Regulation of Adaptive Immunity by the Innate Immune System; Vol. 327. no. 5963, pp. 291-295.
16. **Alan J. Lerner, (2006)** : Diagnostic Criteria in Neurology, edited by
17. **Alberts Bruce, Alexander Johnson, Julian Lewis, Martin Raff, Keith Roberts, and Peter Walters (2002)** : Molecular Biology of the Cell; Fourth Edition. New York and London; Garland Science.
18. **Alimonti JB, Ball TB and Fowke KR (2003)** : "Mechanism of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS.". J. Gen. Virol. 84 (7): 1649–1661.
19. **Alvarez-Lafuente R, Fernández-Gutiérrez B, de Miguel S, et al., (2005)** : "Potential relationship between herpes viruses and rheumatoid arthritis: analysis with quantitative real time polymerase chain reaction". Ann. Rheum. Dis. September 64 (9): 1357–9
20. **Anisur Rahman and David A (2008)** : "Review Article: Systemic Lupus Erythematosus" . Isenberg ,N Engl J Med Feb28; 358 (9): 929–939.
21. **Anwar Al Hammadi (2010)** : <http://emedicin.medscape.com/article/331037>.
22. **Arcus VL, Proft T, Sigrell JA, Baker HM, Fraser JD, and Baker EN (2000)** : Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogenes. J. Mol. Biol. May, 299 (1): 157–68.
23. **Artlett CM, Smith JB, and Jimenez SA (1999)** : New perspectives on the etiology of systemic sclerosis. Mol Med Today. Feb;5 (2): 74-8.
24. **Asano M et al., (1996)** : J. Exp. Med. 184: 387.
25. **Atagunduz P, Appel H, Kuon W, Wu P, Thiel A, Kloetzel PM, et al., (2005)** : HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum 52: 892-901.
26. **Atkinson JP (1986)** : Complement activation and complement receptors in systemic lupus erythematosus. Springer Semin Immunopathol; 9: 179–94.

27. **Augusto C Posadas (2009)** : [http://www.britannica.com/EB checked/
topic/623748/vasculitis](http://www.britannica.com/EBchecked/topic/623748/vasculitis)
28. **Avouac J, Gossec L, and Dougados M (2006)** : "Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review". *Ann. Rheum. Dis.* July, 65 (7): 845–51.
29. **Avouac J, Vicaut E, Bardin T, Richette P (2010)** : Efficacy of joint lavage in knee osteoarthritis: meta-analysis of randomized controlled studies. *Rheumatology (Oxford)*. Feb;49(2): 334-40.
30. **Aw D, Silva AB and Palmer DB (2007)** : "Immunosenesc -ence: emerging challenges for an ageing population", *Immunology* April, 120 (4): 435–46.
31. **Bang H, Egerer K, Gauliard A, et al. (2007)** : "Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis". *Arthritis Rheum.* August 56 (8): 2503–11.
32. **Barclay A.N, van Beek E.M, Cochrane F, and van den Berg T.K, (2005)** : "Membrane proteins with immunoglobulin-like domains-a master superfamily of interaction molecules". *Semin Immunol* 15 (4): 215–23.
33. **Beier K.C et al., (2000)** : *Eur. J. Immunol.* 30:3707.
34. **Belov, Katherine, Janine E. Deakin, Anthony T. Papenfuss, et al., (2006)** : "Reconstructing an Ancestral Mammalian Immune Supercomplex from a Marsupial Major Histocompatibility Complex". *PLoS Biol* 4(3) (e46): e46.
35. **Bennouna S and Denkers EY (2005)** : Microbial antigen triggers rapid mobilization of TNF-alpha to the surface of mouse neutrophils transforming them into inducers of high-level dendritic cell TNF-alpha production. *J Immunol*, 174:4845-4851.
36. **Bergman Y and Cedar H (2004)** : "A stepwise epigenetic process controls immunoglobulin ". *Nat Rev Immunol* 4 (10): 753–61.
37. **Bianchi M.E and Agresti A (2005)** : HMG proteins; dynamic players in gene regulation and differentiation. *Curr. Opin. Genet. Dev.* 15: 496–506.

38. **Binns C (2006)** : Natural Body Guards How Your Killer Cells Get Motivated. Livescience.com. Retrieved on 2007-10-20.
39. **Biron P, Montpetit P, Infante-Rivard C and Lery L. (1988)** : Myasthenia gravis after general anethesia and hepatitis B vaccine. Arch Intern Medicine;148: 2685.
40. **Boghog (2008)** : <http://en.wikipedia.org> en.wikipedia
41. **Bonilla FA, Bernstein IL, Khan DA, et al., (2005)** : Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol.;94: S1-S63.
42. **Borghesi L and Milcarek C (2006)** : "From B cell to plasma cell: regulation of V(D)J recombination and antibody secretion". Immunol Res 36 (1-3): 27–32.
43. **Bostan M, Constantin MC, Nicolau A, Hirt M, Galatiuc C, Matei I, Brasoveanu LI, and Iordachescu D (2002)** : Study of chemotactic activity developed by neutrophils from rheumatoid arthritis patients. Rom Arch Microbiol Immunol , 61: 243-258.
44. **Bottley G, Watherston O, Hiew Y, Norrild B, Cook G and Blair G (2007)** : "High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells". Oncogene.
45. **Bowers and William (2006)** : "Immunology-Chapter nine; Cells involved in immune responses". Microbiology and Immunology On-Line Textbook. USC School of Medicine.
46. **Bowers and William (2006)** : "Immunology-Chapter Thirteen; Immunoregulation". Microbiology and Immunology On-Line Textbook. USC School of Medicine.
47. **Brandt KD, (1974)** : Enhanced extractability of articular cartilage protoglycans in osteoarthritis. Biochem J; 143:475.
48. **Brennan P and Kendrick K (2006)** : "Mammalian social odours: attraction and individual recognition". Philos Trans R Soc Lond B Biol Sci. 361 (1476): 2061-78.

49. **Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, and Treacher DF (2006)** : Neutrophils in development of multiple organ failure in sepsis. *Lancet*, 368: 157-169.
50. **Brüne B (2003)** : "Nitric oxide; NO apoptosis or turning it ON?". *Cell Death Differ.* August **10** (8): 864–9.
51. **Buch T. et al., (2002)** : *Immunity* 16: 707.
52. **Buonpane RA, Moza B, Sundberg EJ and Kranz DM (2005)** : "Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1". *J. Mol. Biol.* October, 353 (2): 308–21.
53. **Burnet F, (1957)** : A modification of Jerne's theory of antibody production using the concept of clonal selection. *Aust J Sci* 20: 67–69.
54. **Buyon JP and Clancy RM (2003)** : "Maternal autoantibodies and congenital heart block: mediators, markers, and therapeutic approach". *Semin. Arthritis Rheum.* December 33 (3): 140–54.
55. **Calame KL, (2001)** : *Nat. Immunol.* 2:1103.
56. **Cannon JG, (2000)** : "Inflammatory Cytokines in Nonpathological States". *News Physiol Sci.* 15: 298–303.
57. **Carding S.R and P.J Egan (2002)** : *Nat. Rev. Immunol.* 2:336.
58. **Carlos J Lozada and Eli Steigelfest (2010)** : <http://emedicin.Medscape.com/article/33147>
59. **Carlos J Lozada, (2010)** : <http://emedicin.medscape.com/article/33147>
60. **Carlson JA, Cavaliere LF, Grant-Kels JM (2006)** : Cutaneous vasculitis ; diagnosis and management. *Clin Dermatol.* Sep-Oct; 24 (5): 414-29.
61. **Carp HJA, Meroni PL and Shoenfeld Y (2008)** : Autoantibodies as predictors of pregnancy complications. *Rheumatology* 47(Suppl 3): iii6–8.
62. **Carroll MC, (1998)** : The role of complement and complement receptors in the regulation of immunity. *Ann Rev Immunol*, 16: 545-568.

63. **Carter JD and Hudson AP (2009)** : reactive arthritis: clinical aspects and medical management. *Rheum Dis Clin North Am.* Feb; 35 (1): 21-44.
64. **Carter JD, Valeriano J, Vasey FB (2004)** : Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to chlamydia-induced arthritis. A prospective, randomized 9-month comparison. *J Rheumatol.* Oct; 31(10): 1973-80.
65. **Casali P and Zan H (2004)** : "Class switching and Myc translocation: how does DNA break?". *Nat. Immunol.* 5 (11): 1101–3.
66. **Castelino M and Barton A (2010)** : *Curr Opin Rheumatol.* Genetic susceptibility factors for psoriatic arthritis. Mar;22(2): 152-6.
67. **Ceredig R et al., (2000)** : *Eur. J. Immunol.* 30:759.
68. **Cervera R, Khamashta MA, Font J, et al., (2005)** : Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. *Medicine (Baltimore)*; 72: 113–24.
69. **Chandra, J, Wiedmer, T, Sims, PJ, Henter, JI, Orrenius, S and Samali, A (1999)** : malnutrition is the most common cause of immunodeficiency, *Biophys. Res. Commun*; 266 (2): 504-11.
70. **Chapoval A. et al., (2001)** : *Nat. Immunol.* 2: 269.
71. **Chen G, Goeddel DV (2002)** : "TNF-R1 signaling: a beautiful pathway". *Science* 296 (5573): 1634–5.
72. **Chen HA, Lin KC, Chen CH, et al., (2005)** : The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. *Ann Rheum Dis.* Jan; 65(1): 35-9.
73. **Chen K, Xu W, Wilson M, He B, Miller NW, Bengtén E, Edholm ES, Santini PA, Rath P, Chiu A, Cattalini M, Litzman J, B Bussel J, Huang B, Meini A, Riesbeck K, Cunningham-Rundles C, Plebani A and Cerutti A (2009)** : "Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils". *Nature Immunology* 10 (8): 889–98.
74. **Cheng P.C. et al., (1999)** : *J. Exp. Med.* 190:1549.

75. **Cherukuri A. et al., (2001)** : Immunity 14:169.
76. **Chiarugi A, Moskowitz MA (2002)** : "PARP-1—a perpetrator of apoptotic cell death?". Science **297** (5579): 259–63.
77. **Christopher Sjöwall, Anders A Bengtsson, Gunnar Sturfelt and Thomas Skogh (2004)** : Arthritis Res Ther, 6:R87-R94.
78. **Coenen D, Verschueren P, Westhovens R, Bossuyt X (2007)** : "Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis". Clin. Chem. 53 (3): 498–504.
79. **Coornaert B, Carpentier I and Beyaert R (2009)** : The transcription factor NF-kappaB in inflammation and immunity; May Nature. 4;459(7247): 712-6.
80. **Coornaert B, Carpentier I, and Beyaert R (2009)** : inappropriate functioning of the immune system is linked to immune disorders Nat. Immunol. 4;459:712(6).
81. **Coornaert B, Vincent J, Carpentier I, et al., (2009)** : "Apoptosis is an active process." Int. Immunol. 8:765.
82. **Cotran; Kumar, Collins (1998)** : Robbins Pathologic Basis of Disease. Philadelphia: W.B Saunders Company.
83. **Coyle A.J. et al., (2000)** : Immunity 13:95.
84. **Cream JJ, Leven GM, and Canan CD (1971)** : Erythema elevatum diutinum. Br J Dermatol; 84: 393-9.
85. **Cutolo M, Capellino S and Straub RH (2008)** : Oestrogens in rheumatic diseases:friend or foe? Rheumatology 47(Suppl 3): iii2–5.
86. **Dadi HK, Simon AJ and Roifman CM (2003)** : Effect of maturation on alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. N Engl J Med. Nov 6;349 (19):1821-8.
87. **Dana Jacobs-Kosmin, (2010)** : <http://www.britannica.com/EBchecked/topic/623748/vasculitis>
88. **Daniel Ricklin and John D Lambris (2007)** : Nature Biotechnology 25, 1265 - 1275 Complement-targeted therapeutics.

89. **David F, Farley J, Huang H, Lavoie JP and Laverty S (2007) :** Cytokine and chemokine gene expression of IL-1beta stimulated equine articular chondrocytes. *Vet Surg.* Apr; 36(3): 221-7. Erratum in: *Vet Surg.* Jul; 37(5): 499.
90. **David, Male, Roitt I et al., (2006) :** *J Immunology* (7th ed) London; Mosby.
91. **Davidson A and Diamond B (2001) :** Autoimmune diseases. *N Engl J Med* 345: 340–350.
92. **Davies DJ, Moran JE, Niall JF and Ryan GB (1982) :** Segmental necrotising glomerulonephritis with antineutrophil antibody; possible arbovirus aetiology. *Brit Med J*; 285: 606.
93. **D'Cruz D, Chesser AM, Lightowler C, et al., (1995) :** Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with antithyroid drug treatment. *Br J Rheumatol*; 34:1090-1.
94. **D'Cruz D, Chesser AM, Lightowler C, et al., (1995) :** "Drug induced vasculitis". *Br J Rheumatol*; 34:1092-3.
95. **Dean Laura, (2005) :** "Chapter 4: Hemolytic disease of the newborn". *Blood Groups and Red Cell Antigens.* NCBI Bethesda (MD): National Library of Medicine (US).
96. **Decker P, (2006) :** Nucleosome autoantibodies. *Clin. Chim. Acta.* 366: 48–60.
97. **Dejean LM, Martinez-Caballero S, Manon S, Kinnally KW (2006) :** "Regulation of the mitochondrial apoptosis-induced channel, MAC, by BCL-2 family proteins". *Biochim. Biophys. Acta* February 1762 (2): 191–201.
98. **Del Rosso A, Generini S, Pignone A, et al., (1999) :** Vasculitides secondary to systemic disease. *Clin Dermatol*; 17: 533-47.
99. **Diane L Kamen, Fredrick M Wigley, and Alan N Brown (2006) :** *J Rheumatol*; 33:1886–8
100. **Dijstelbloem HM, Bijl M, Fijnheer R, et al., (2006) :** Fcgamma receptor polymorphisms in systemic lupus erythematosus: association

with disease and in vivo clearance of immune complexes. *Arthritis Rheum*; 43: 2793–800.

101. **Direskeneli H, (2001) :** Behcet's disease; infectious aetiology, new autoantigens, and HLA-B51. *Ann Rheum Dis*. Nov; 60 (11): 996-1002.
102. **Doggrell S, (2003) :** "Is natalizumab a breakthrough in the treatment of multiple sclerosis?". *Expert Opin Pharmacother* 4 (6): 999–1001.
103. **Domínguez-López ML, Ortega-Ortega Y, Manríquez-Raya JC, Burgos-Vargas R, Vega-López A, García-Latorre E (2009) :** *Clin Exp Rheumatol*. Jul-Aug;27(4): 626-32.
104. **Doria A, Bajocchi G, Tonon M, Salvarani C (2008) :** Pre-pregnancy counselling of patients with vasculitis. *Rheumatology* 47(Suppl 3): iii13–15.
105. **Durandy A (2003) :** "Activation-induced cytidine deaminase: a dual role in class-switch recombination and somatic hypermutation". *Eur. J. Immunol*. 33 (8): 2069–73.
106. **E.M Tan, P.H Schur, R.I Carr, and H.G Kunkel (1966) :** Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. *J. Clin. Invest.* 45:1732–1740.
107. **Edelman GM and Gally JA (1962) :** "The nature of Bence-Jones proteins. Chemical similarities to polypeptide chains of myeloma globulins and normal gamma-globulins". *J. Exp. Med.* 116: 207–27.
108. **Edwards JC and Cambridge G (2006) :** "B-cell targeting in rheumatoid arthritis and other autoimmune diseases.". *Nature Reviews Immunology* 6 (5): 394–403.
109. **Egan CA, Taylor TB, Meyer LJ, et al., (1999) :** IgA1 is the major IgA subclass in cutaneous blood vessels in Henoch-Schönlein purpura. *Br J Derm*;141(5): 859-62.
110. **Egger G, Klemm C, Spendel S, Kaulfersch W, and Kenzian H (1994) :** Migratory activity of blood polymorphonuclear leukocytes during juvenile rheumatoid arthritis, demonstrated with a new whole-blood membrane filter assay. *Inflammation*, 18:427-441.

111. **El Benna J, Hayem G, Dang PM, Fay M, Chollet-Martin S, Elbim C, Meyer O, Gougerot-Pocidalo MA (1997) :** NADPH oxidase priming and p47phox phosphorylation in neutrophils from synovial fluid of patients with rheumatoid arthritis and spondylarthropathy. *Inflammation*, 26: 273-278.
112. **Eleonora Market and F. Nina Papavasiliou (2003) :** V(D)J Recombination and the Evolution of the Adaptive Immune System, *PLoS Biology*1(1); e16.
113. **Elkhan O, Yaron M, Caspi D (1999) :** Minocycline-induced autoimmune syndromes; An overview. *Sem Arthr Rheum*;28(6): 392-7.
114. **Emma Farne (2006) :** Labelled diagram of a cell undergoing apoptosis. File adapted from a German Wikipedia entry: <http://de.wikipedia.org/wiki/Bild:Apoptose-german.png>
115. **Erkan D, Patel S, Nuzzo M, et al., (2008) :** Management of the controversial aspects of the antiphospholipid syndrome pregnancies: a guide for clinicians and researchers. *Rheumatology* 47(Suppl 3): iii23–7.
116. **Ethuin F, Gerard B, Benna JE, Boutten A, Gougereot-Pocidalo MA, Jacob L, Chollet-Martin S (2004) :** Human neutrophils produce interferon gamma upon stimulation by interleukin-12. *Lab Invest*, 84: 1363-1371.
117. **Eustice R (2006) :** Autoantibodies, instead of acting against foreign invaders as normal antibodies do, attack the body's own cells About.com.arthritis. *Proc Natl Acad Sci U S A* ; 87: 4111-4114.
118. **Evans MJ, MacLaughlin S, Marvin RD, et al., (2006) :** Estrogen decreases in vitro apoptosis of peripheral blood mononuclear cells from women with normal menstrual cycles and decreases TNF-alpha production in SLE but not in normal cultures. *Clin Immunol Immunopathol*; 82: 258–62.
119. **Falk RJ, Terrell RS, Charles LA and Jennette JC (1990) :** Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. *Proc Natl Acad Sci U S A*;87: 4115-4119.

120. **Fanning LJ, Connor AM and Wu GE (1996)** : "Development of the immunoglobulin repertoire". Clin. Immunol. Immunopathol. 79 (1): 1–14.
121. **Feldmann M and Maini R (2001)** : "Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?". Annu Rev Immunol 19: 163–96.
122. **Ferrell PB, Aitcheson CT, Pearson GR, and Tan EM (1981)** : "Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis" March. J. Clin. Invest. 67 (3): 681–7.
123. **Fesik SW, Shi Y. (2001)** : "Controlling the caspases". Science 294 (5546): 1477–8.
124. **Firestein Gary, Panayi Gabriel, Wollheim Frak (2006)** : Rheumatoid arthritis, (2nd Ed.) 608p.
125. **Firestein, Gary S (2005)** : Immunologic Mechanisms in the Pathogenesis of Rheumatoid Arthritis Journal of Clinical Rheumatology, June vol 11, issue 3, ppS39, S44.
126. **Fischbach FT and Dunning MB (2004)** : Manual of Laboratory and Diagnostic Tests, 7th ed. Philadelphia: Lippincott Williams and Wilkins.
127. **Foell D and Roth J (2004)** : Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum, 50: 3762-3771.
128. **Font J, Ramos-Casals M, Cervera R, et al., (1998)** : Antineutrophil cytoplasmic antibodies in primary Sjögren's Syndrome: Prevalence and clinical significance. Br J Rheum;37:1287-91.
129. **Franceschini F and Cavazzana I (2005)** : "Anti-Ro/SSA and La/SSB antibodies". Autoimmunity February 38 (1): 55–63.
130. **Freeman G.J. et al., (2000)** : Science 262: 909.
131. **Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, Harms E, Sorg C, Roth J (2000)** : Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum, 43: 628-637.

132. **GC Fanning, KI Welsh, C Bunn, R Du Bois and CM Black :**
Tissue Typing in Systemic sclerosis Volume 45, Supplement 1,
October , pp. 23-25(3).
133. **Geisberger R, Lamers M and Achatz G (2006) :** " the dual
expression of IgM and IgD". Immunology 118 (4): 429–37.
134. **Gene Mayer (2006) :** "Immunology-Chapter Three; Adaptive
Immunity". Microbiology and Immunology On-Line Textbook. USC
School of Medicine.
135. **Gene Mayer (2006) :** "Immunology - Chapter Two; Complement".
Microbiology and Immunology On-Line Textbook. USC School of
Medicine.
136. **Gene Mayer (2006) :** Immunology - Chapter ten ,7th ed; major
histocompatibility complex (MHC) and Tcell receptors - role in
immune responses.
137. **Gergely P Jr and Poor G (2004) :** Relapsing polychondritis. Best
Pract Res Clin Rheumatol. Oct;18(5): 723-38.
138. **Ghaffar, Abdul (2006) :** "Immunology-Chapter Seventeen;
Hypersensitivity Reactions". Microbiology and Immunology On-Line
Textbook. USC School of Medicine."
139. **Ghersetich I, Comacchi C, Jorizzo JL, et al., (1999) :** Proposal for a
working classification of cutaneous vasculitis. Clinics in
Dermatology;17: 499-503.
140. **Girardi M (2006) :** "Immunosurveillance and immunoregula- tion by
gammadelta T cells". The Journal of Investigative Dermatology Jan.
126 (1): 25–31.
141. **Goeddel, DV. (2009) :** "Connection Map for Tumor Necrosis Factor
Pathway". Science. http://stke.sciencemag.org/cgi/cm/CMP_7107.
142. **Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon
JM, Burt NP, Guiducci C, Parkin M, Gates C, Plenge RM,
Behrens TW, Wither JE, Rioux JD, Fortin PR, Graham DC, Wong
AK, Vyse TJ, Daly MJ, Altshuler D, Moser KL, Gaffney PM (2008)**

: Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. *Nat Genet* , 40:1059-1061.

143. **Gran JT, Husby G, and Hordvik M (1985)** : Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. *Ann Rheum Dis* 44: 359-367, 1985.
144. **Greiner A, Plischke H, Kellner H, and Gruber R (2005)** : "Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis". *Ann. N. Y. Acad. Sci.* 1050: 295–303.
145. **Greizard P, Chafi M, Philippot V, Perrot H and Faisant M (1996)** : Cutaneous lupus erythematosus and buccal aphthosis after hepatitis B vaccination in a 6-year-old child. *Ann Dermatol Venereo*;123: 657-659.
146. **Grom AA and Hirsch R (2000)** : T-cell and T-cell receptor abnormalities in the immunopathogenesis of juvenile rheumatoid arthritis. *Current Op Rheumatol*, 12: 420-424.
147. **Guermonprez P, Valladeau J, Zitvogel L, Théry C, Amigorena S (2002)** : "Antigen presentation and T cell stimulation by dendritic cells". *Annual Review of Immunology* 20: 621–67.
148. **Hahn, B.H (1998)** : Antibodies to DNA. *N. Engl. J. Med.* 338:1359–1368.
149. **Hajo Haase and Lothar Rink (2009)** : Institute of Immunology, The immune system and the impact of zinc during aging, Germany *Immunity and Ageing* 30, 52074 Aachen , 6:9.
150. **Hardy R.R. and Hayakawa K. (2001)** : *Annu. Rev. Immunol.* 19:595.
151. **Hasegawa M, Sato S, Nagaoka T, Fujimoto M and Takehara K (2003)** : *Dermatology*; Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma; 207 (2): 141-7.

152. **Haseley LA, Wisnieski JJ, Denburg MR, et al., (2005)** : Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to Fc gamma RIIA alleles. *Kidney Int*;52:1375–80.
153. **Häupl T, Ustensen M, Grützkau A, Burmester G-R, and Villiger PM (2008)** : Interaction between rheumatoid arthritis and pregnancy: correlation of molecular data with clinical disease activity measures. *Rheumatology* 47(Suppl 3): iii19–22.
154. **Hautmann and Lotti T (1999)** : The many faces of cutaneous vasculitis. *Clin Derm*;17: 515-31.
155. **Hayakawa K. et al., (1999)** : *Science* 285:113.
156. **Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al., (2008)** : Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. *Arthritis Rheum.* Jan ;58(1): 15-25.
157. **Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D, et al., (2007)** : A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. *Nat Genet*;35: 349–56.
158. **Herroelen L, De Keyser J and Ebinger G (1991)** : Central-nervous system demyelination after immunisation with recombinant hepatitis B vaccine. *Lancet*;338: 1174.
159. **Hewett D, Samuelsson L, Polding J, Enlund F, Smart D, Cantone K, et al., (2002)** : Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. *Genomics*;79: 305–14.
160. **Hinks A, Ke X, Barton A, et al., (2009)** : Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis. *Arthritis Rheum.* Jan; 60(1): 251-7.
161. **Holtmeier W and Kabelitz D (2005)** : "gammadelta T cells link innate and adaptive immune responses". *Chemical Immunology and Allergy* 86: 151–83.

162. **Holtmeier W and Kabelitz D (2005)** : "gammadelta T cells link innate and adaptive immune responses". *Chemical Immunology and Allergy* 86: 151–83.
163. **Huber R (1980)** : "Spatial structure of immunoglobulin molecules". *Klin Wochenschr* 58 (22): 1217–31.
164. **Hutloff A. et al., (1999)** : *Nature* 397: 263.
165. **I. Baumann, W. Kolowos, R.E. Voll, B. Manger, U. Gaipl, W.L. Neuhuber, T. Kirchner, J.R. Kalden, and M. Herrmann (2002)** : Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. *Arthritis Rheum.* 46:191–201.
166. **Iain B McInnes and Georg Schett (2007)** : Cytokines in the pathogenesis of rheumatoid arthritis *Nature Reviews Immunology* , June 7, 429-442.
167. **Inman RD (2009)** : Innate immunity of spondyloarthritis; the role of toll-like receptors. *Adv Exp Med Biol.*;649: 300-9.
168. **Israel F. Charo and Richard M. Ransohoff (2006)** : The many roles of chemokines and chemokine receptors in inflammation; Volume 354: 610-621.
169. **Itoh K, Sakakibara M, Yamasaki S, Takeuchi A, Arase H, Miyazaki M, et al., (2006)** : Cutting edge: negative regulation of immune synapse formation by anchoring lipid raft to cytoskeleton through Cbp-EBP50-ERM assembly. *J Immunol*;168: 541–4.
170. **J. Tian, A.M. Avalos, S.Y. Mao, B. Chen, K. Senthil, H. Wu, P. Parroche, S. Drabic, D. Golenbock, C. Sirois, et al., (2007)** : Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. *Nat. Immunol.* 8:487–496.
171. **Janeway CA, et al., (2008)** : *Immunobiology; the immune system in health and disease.* 7th ed. New York: Garland Science/Churchill Livingstone.

172. **Janeway Charles A.; Travers, Paul; Walport, Mark; Shlomchik, Mark(2005)** : Immunobiology; the immune system in health and disease (6th ed), Garland Science.
173. **Jarvis JN, Dozmorov I, Jiang K, Frank MB, Szodoray P, Alex P, Centola M (2004)** : Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis. *Arthritis Res Ther* , R15-R32.
174. **Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski T, Kumar V, Beutner EH (1986)** : Scl 70 antibody--a specific marker of systemic sclerosis. *Br J Dermatol* Oct;115(4) :393-401.
175. **Jasin HE, (1989)** : Immune mechanisms in osteoarthritis. *Semin Arthritis Rheum*; 18:86
176. **Jayne D and Tyndall A (2004)** : Autologous stem cell transplanta - tion for systemic lupus erythematosus. *Lupus* 13(5), 359–365.
177. **Jefferson R Roberts, (2010)** : <http://www.britannica.com/EBchecked/topic/623748/vasculitis>.
178. **Jeffrey P Callen, (2009)** : <http://emedicine.medscape.com/article/33137-vasculitis>.
179. **Jelaska A, Arakawa M, Broketa G, Korn JH (1996)** : Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts. Increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. *Arthritis Rheum.* Aug; 39 (8): 1338-46.
180. **Jiang K, Chen Y, Xu C-S, Jarvis JN (2004)** : T Cell activation by soluble C1q-bearing immune complexes: implications for the pathogenesis of rheumatoid arthritis. *Clin Exp Immunol.*, 131: 61-67.
181. **Jin, Y., L. Fuller, G. Ciancio, G.W. Burke III, A.G. Tzakis, C. Ricordi, J. Miller, and V. Esquenzai. (2004)** : Antigen presentation and immune regulatory capacity of immature and mature-enriched

antigen presenting (dendritic) cells derived from human bone marrow. Hum. Immunol., 65: 93–103.

182. **Johansson SG, (2006) :** "The discovery of immunoglobulin E". Allergy and asthma proceedings: the official journal of regional and state allergy societies 27 (2 Suppl 1): S3–6.
183. **John Reveille and Matthew Brown (2010) :** Nature Genetics 10. [Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci](#), January.
184. **John Wiley (2007) :** Systemic lupus erythematosus (SLE). Finnish Medical Society Duodecim EBM Guidelines. Evidence-Based Medicine.
185. **Johnson E and Brehm-Stecher B (2006) :** "Single-cell microbiology; tools, technologies, and applications". Microbiol Mol Biol Rev 68 (3): 538–59.
186. **Jon Giles (2009) :** Do Occupational Exposures Increase the Risk of Death from Systemic Autoimmune Disease? June 34 (5): 352
187. **Jones DA, Jennette JC, Falk RJ (1990) :** Goodpasture's syndrome revisited; A new perspective on glomerulonephritis and alveolar hemorrhage. N C Med J;51: 411-5.
188. **Jonuleit H, et al., (2000) :** J. Exp. Med. 192:1213.
189. **Jun JB, Kuechle M, Harlan JM, and Elkon KB (2003) :** Fibroblast and endothelial apoptosis in systemic sclerosis. Curr Opin Rheumatol. Nov; 15 (6): 756-60.
190. **K Hoebe, E Janssen and B Beutler (2004) :** The interface between innate and and adaptive immunity and MHC; Nature Immunology; Oct., vol. 5:10.
191. **K. Hanke, (2009) :** Arthritis Research and Therapy, 11:R28.
192. **Kallenberg CG, Mulder AH, Tervaert JW (1992) :** Antineutrophil cytoplasmic antibodies (ANCA); A still-growing class of autoantibodies in inflammatory disorders. Am J Med, 93: 675.
193. **Kallenberg M, (2008) :** Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun. February-March; 30: 29-36.

194. **Kallenberg M, Heeringa P, Stegeman CA (2006) :** Mechanisms of disease: pathogenesis and treatment of ANCA-associated vasculitis. *Nat Clin Pract Rheumatol*. December; 2: 661-670.
195. **Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L (2006) :** Early T cell activation in the skin from patients with systemic sclerosis. *Ann Rheum Dis*. Aug;64 (8): 1233-5.
196. **Kang SM and Compans RW (2009) :** Host responses from innate to adaptive immunity After vaccination: Molecular and cellular events. *Mol Cells* Feb 28;27(1): 5-14.
197. **Kanneganti TD, Lamkanfi M and Núñez G (2007) :** Intracellular NOD-like receptors in host defense and disease. *Immunity*. Oct;27 (4): 549-59.
198. **Kariyawasam HH and Robinson DS (2006) :** "The eosinophil: the cell and its weapons, the cytokines, its locations". *Seminars in Respiratory and Critical Care Medicine* 27(2): 117–27.
199. **Karp DR, Marthandan N, Marsh SG, Ahn C, Arnett FC, Deluca DS, Diehl AD, Dunivin R, Eilbeck K, Feolo M, Guidry PA, Helmberg W, Lewis S, Mayes MD, Mungall C, Natale DA, Peters B, Petersdorf E, Reveille JD, Smith B, Thomson G, Waller MJ, and Scheuermann RH (2010) :** "Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis.". *Human Molecular Genetics* 19 (4): 707–719.
200. **Katharina Hanke, (2009):** Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients. *Arthritis Research and Therapy*, 11: R22.
201. **Kavanaugh A, Tomar R, Reveille J, Solomon DH, and Homburger HA (2000) :** Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. *American College of Pathologists. Arch Pathol Lab Med*;124: 71-81.
202. **Kawai T and Akira S (2006) :** "Innate immune recognition of viral infection" *Nature Immunology* 7(2): 131–7.

203. **Kawakami T, Tsutsumi Y, Soma Y (2009)** : Limited cutaneous systemic sclerosis induced by paclitaxel in a patient with breast cancer. *Arch Dermatol.* Jan;145(1): 97-8.
204. **Kawakami T, Yamazaki M, Mizoguchi M, Soma Y (2008)** : High titer of serum antiphospholipid antibody levels in adult Henoch-Schönlein purpura and cutaneous leukocytoclastic angiitis. *Arthritis Rheum.* Apr 15;59 (4): 561
205. **Kee B.L. and Murre C. (2001)** : *Curr. Opin. Immunol.* 13:180.
206. **Kelly. J., (2009)** : The Cutoff Points of Antinuclear Antibody (ANA) with High Negative and Positive Predictive Values. Analysis of 5655 Cases. Aug 12, *Musculoskeletal Report.*
207. **Kelton. JG, (1981)** : Vaccination-associated relapse in immune thrombocytopenia. *JAMA*; 245: 369-71.
208. **Keren DF, (2002)** : *Clin Lab Med.* Antinuclear antibody testing.. Warde Medical Laboratory, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48108, USA. Jun;22 (2): 447-74.
209. **Kimball, (2010)** : hla.alleles.org
210. **Kiss E, Csipo I, Cohen JH, et al., (2004)** : CR1 density polymorphism and expression on erythrocytes of patients with systemic lupus erythematosus. *Autoimmunity*;25: 53–8.
211. **Klein J and Sato A (2000)** : "The HLA system. Second of two parts". *N. Engl. J. Med.* September, 343 (11): 782–6.
212. **Klinman DM, Shirai A, Ishigatsubo Y, et al., (2003)** : Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus. *Arthritis Rheum*; 34: 1404–10.
213. **Kokkonen, (2010)** : *H. Arthritis and Rheumatism*, Feb. 2, vol 62: pp 383-391.
214. **Koopman, William, et al., (2003)** : *Clinical Primer of Rheumatology.* Philadelphia: Lippincott.
215. **Kouskoff V and Nemazee D (2001)** : *Life Sci.* 69:1105.
216. **Kouskoff V. et al., (2000)** : *Science* 287:2501.
217. **Kovacs B, Maus MV, Riley JL, et al., (2002)** : "Human CD8+ T cells do not require the polarization of lipid rafts for activation and

proliferation". Proceedings of the National Academy of Sciences of the United States of America November 99 (23): 15006–11.

218. **Krishna (2009) :** <http://www.everydayhealth.com/autoimmune-disorder,EverydayHealth>Women,andAutoimmedisorders.>"
219. **Krivosikova M, Dallos T, Maslinski W, Buc M, Bratisl L Listy(2009) :** crucial role of BAFF in the pathogenesis of RA and SLE ;110 (3): 137-45.
220. **Krueger G, Langley R, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley L and Lebwohl M (2007) :** "A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis". N Engl J Med 356 (6): 580–92.
221. **Krueger G, Langley R, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley L, Lebwohl M (2007) :** " susceptibility variants of the MHC as well as variants that alter T cell responses during development, during thymic selection, or in the periphery in psoriasis". N Engl J Med 356 (6): 580–92.
222. **Krummel M. and J. Allison (1995) :** J. Exp. Med. 182:459.
223. **Kubach J, Becker C, Schmitt E, Steinbrink K, Huter E, Tuettenberg A, Jonuleit H (2005) :** "Dendritic cells: sentinels of immunity and tolerance". Int J Hematol 81 (3): 197–203.
224. **Kumar H, Kawai T and Akira S (2009) :** Pathogen recognition in the innate immune response Biochem J Apr 28;420 (1): 1-16.
225. **Kurosaki T. (2002) :** Nat. Rev. Immunol. 2: 354.
226. **Kurowski K and Boxer RW (2008) :** Food allergies; detection and management. American Family Physician. June:77:12.
227. **Kwara A, Ramachandran G, Swaminathan S (2010) :** Expert Opinion on Drug Metabolism and Toxicology January, 6 (1): 55–68.
228. **L Maes (2010) :** Antibodies against PM/Scl-75 and PM/ Scl-100 are independent markers for different subsets of systemic sclerosis patients. Clin Chim Acta. Jul 4;411(13-14): 965-71.
229. **LaFleur-Brooks, M (2008) :** Exploring Medical Language: A Student-Directed Approach, 7th Edition. St. Louis, Missouri, USA: Mosby Elsevier. pp. 398.

230. **Lai-Shan Tam, Jieruo Gu and David Yu (2010) :** Genetics Pathogenesis of ankylosing spondylitis (AS), *Nature Reviews Rheumatology* July 6, 399-405.
231. **Larsson M. et al., (2001) :** *Trends Immunol.* 22:141.
232. **Latchman Y. et al., (2001) :** *Nat. Immunol.* 2:261.
233. **Lauhio A, Leirisalo-Repo M, Lähdevirta J, Saikku P, Repo H (1991) :** Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. *Arthritis Rheum.* Jan ; 34(1): 6-14.
234. **Laurent M. Dejean, Sonia Martinez-Caballero, Kathleen W. Kinnally (2006) :** "Is MAC the knife that cuts cytochrome c from mitochondria during apoptosis?". *Cell Death and Differentiation* 13 (8): 1387–5.
235. **Le Y, Zhou Y, Iribarren P and Wang J (2004) :** "Chemokines and chemokine receptors: their manifold roles in homeostasis and disease". *Cellular and Molecular Immunology* April 1(2): 95–104.
236. **Lebwohl M (2003) :** Psoriasis. *Lancet*; 361:1197–204.
237. **Lechner O. et al., (2001) :** *Curr. Biol.* 11: 587.
238. **Lee DM and Schur PH (2003) :** Clinical utility of the anti-CCP assay in patients with rheumatic diseases. *Ann Rheum Dis.* Sep;62 (9): 870-4.
239. **Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A (2000) :** Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. *Science* , 289: 2350-2354.
240. **Lefkowitz DL, Gelderman MP, Fuhrmann SR, Graham S, Starnes JD III, Lefkowitz SS, Bollen A, and Moguilevsky N (1999) :** Neutrophilic myeloperoxidase-macrophage interactions perpetuate chronic inflammation associated with experimental arthritis. *Clin Immunol*, 91: 145-155.
241. **Lehnhardt FG, Scheid C, Holtik U et al., (2006) :** Autologous blood stem cell transplantation in refractory systemic lupus erythematoses with recurrent longitudinal myelitis and cerebral infarction. *Lupus* 15(4): 240–243.
242. **Lenschow D.J et al., (1996) :** *Annu. Rev. Immunol.* 14: 233.

243. **Lenzi M, Frisoni M, Mantovani V, et al., (1998)** : Haplotype HLA B-8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. *Blood*; 91: 2062-6.
244. **LeRoy EC, Black C, Fleischmajer R, et al., (1988)** : Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. *J Rheumatol.* Feb; 15(2): 202-5.
245. **Li W, Wang M, Irigoyen P, and Gregersen PK (2006)** : Inferring causal relationships among intermediate phenotypes and biomarkers: a case study of rheumatoid arthritis. *Bioinformatics*, 22: 1503-1507.
246. **Lieber MR, Yu K and Raghavan SC (2006)** : "Roles of nonhomologous DNA end joining, V(D)J recombination, and class switch recombination in chromosomal translocations". *DNA Repair (Amst.)* 5 (9-10): 1234–45.
247. **Lindenmann Jean (1984)** : "Origin of the Terms 'Antibody' and 'Antigen'". *Scand. J. Immunol.* 19 (4): 281–5.
248. **Ling V et al., (2000)** : *J. Immunol.* 164:1653.
249. **Linker-Israeli M, Deans RJ, Wallace DJ, et al., (2005)** : Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. *J Immunol*; 147: 117–23.
250. **Liossis SN, Kovacs B, Dennis G, et al., (2005)** : B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. *J Clin Invest* 98: 2549–57.
251. **Litman GW, Cannon JP, and Dishaw LJ (2005)** : "Reconstructing immune phylogeny: new perspectives". *Nature Reviews. Immunology* 5(11):866–79.
252. **Little MA et al., (2005)** : Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions *in vivo*. *Blood* 106: 2050-2058.
253. **Liu LJ, Chen M, Yu F, Zhao MH, and Wang HY (2008)** : Evaluation of a new algorithm in classification of systemic vasculitis. *Rheumatology (Oxford)*. May;47(5): 708-12.
254. **Llewelyn M and Cohen J (2002)** : "Superantigens: microbial agents that corrupt immunity". *Lancet Infect Dis* March 2 (3): 156–62.
255. **Lohmann T. et al., (1996)** : *J. Autoimmun.* 9: 385.

256. **Longmore M, Wilkinson I.B and Rajagopalan S.R (2004)** : Oxford Handbook of Clinical Medicine; 6th ed, OUP.
257. **Lotti TM, Comacchi C, and Gersetich I.(1999)** : Cutaneous necrotizing vasculitis: Relation to systemic disease. *Rheumaderm* ; 55: 115-25.
258. **Lovy MR, Starkebaum G, Uberoi S (1996)** : "Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis." *J. Rheumatol* 23 (6): 1238–9.
259. **Luime JJ, Colin EM, Hazes JM, Lubberts E (2009)** : " Additional value of cytokines in the diagnostic and prognostic work-up of patients with rheumatoid arthritis? A systematic review.". *Ann Rheum Dis.* Mar 15.69 (2): 337–44.
260. **M K Crow (2004)** : *Autoimmun Rev.* Nov; 3 (7-8): 500-4.
261. **M K Crow (2008)** : *Arthritis Research and Therapy* , 10:126.
262. **M. Adler, S. Schulz, and M. Spengler (2009)** : Cytokine Quantification in Drug Development: A comparison of sensitive immunoassay platforms. Chimera Biotech. (Report).
263. **Mackay C.R. (2001)** : *Nat. Immunol.* 2:95.
264. **Maeda Y. et al., (2001)** : *Immunobiology* 204:442.
265. **Mankin, HJ, Dorfman, HD, Lipiello, L, et al., (1971)** : Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. II. Correlation of morphology with metabolic data. *J Bone Joint Surg*; 53A: 523.
266. **Maria Trojanowska, (2010)** : *Nature Reviews Rheumatology*, 10.1038/nrrheum.102
267. **Mariathasan S et al., (2001)** : *J. Immunol.* 167: 4966.
268. **Mark P. Mattson & Sic L. Chan (2003)** : Calcium orchestrates apoptosis. *Nature Cell Biology* 5, 1041 - 1043.
269. **Marrack JR, (1938)** : *Chemistry of antigens and antibodies* (2nd ed) London: His Majesty's Stationery Office.
270. **Martensson G and Ceredig S (2000)** : *J. Immunol.* 147:766.
271. **Martin F Flajnik and Masanori Kasahara (2010)** : Origin and evolution of the adaptive immune system: genetic events and selective pressures' *Nature Reviews Genetics* 11, 47-59.

272. **Martin P and Leibovich SJ (2005)** : "Inflammatory cells during wound repair: the good, the bad and the ugly". *Trends in Cell Biology* November,15(11):599–607.
273. **Masaki Nagai, (2004)**: *Journal of Investigative Dermatology* 122, 594–601.
274. **Matera L, (1997)** : Action of pituitary and lymphocyte prolactin. *Neuroimmunomodulation*;4:171–80.
275. **Matsushita T, Hasegawa M, Matsushita Y, Echigo T, Wayaku T, Horikawa M, Ogawa F, Takehara K, and Sato S (2007)** : *Exp Dermatol.*, Feb;16 (2): 87-93.
276. **Matteson EL, (1999)** : A history of early investigation in polyarteritis nodosa. *Arthritis Care Res*; 12: 294-302.
277. **Mattu T, Pleass R, Willis A, Kilian M, Wormald M, Lellouch A, Rudd P, Woof J and Dwek R (1998)** : "The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions". *J Biol Chem* 273 (4): 2260–72.
278. **Matzinger P, (2002)** : "The danger model: a renewed sense of self". *Science* April, 296(5566): 301–5.
279. **May E, Dulphy N, Frauendorf E, Duchmann R, Bowness P, Lopez de Castro JA, et al., (2002)** : Conserved TCR beta chain usage in reactive arthritis; evidence for selection by a putative HLA-B27-associated autoantigen. *Tissue Antigens* 60: 299-308.
280. **McCombe PA, Greer JM, and Mackay IR (2009)** : Sexual dimorphism in autoimmune disease. *Curr Mol Med*. Dec;9(9):1058-79.
281. **McGonagle, Dennis, Aziz, Azad, Dickie, Laura J., McDermott, Michael F (2009)** : *Infections and Immunity: Immune Regulation and Inflammation*; Volume 65 - Issue 5 Part 2 - pp 38R-45R.
282. **McHeyzer-Williams LJ, Malherbe LP and McHeyzer-Williams MG (2006)** : "Helper T cell-regulated B cell immunity". *Current Topics in Microbiology and Immunology* 311: 59–83.
283. **McMurray RW, Ndebele K, Hardy KJ, et al., (2007)** : 17-beta-estradiol suppresses IL-2 and IL-2 receptor. *Cytokine*;14: 324–33.

284. **Medzhitov R, (2007) :** "Recognition of microorganisms and activation of the immune response". *Nature* 449 (7164): 819–26.
285. **Meffre E, et al., (2000) :** *Nat. Immunol.* 1:207.
286. **Meier CR, Sturkenboom MC, Cohen AS, et al.,(1998) :** Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. *J Rheumatol*; 25: 1515–19.
287. **Messmer, D., H. Yang, G. Telusma, F. Knoll, J. Li, B. Messmer, K.J. Tracey, and N. Chiorazzi (2004) :** High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. *J. Immunol.* 173:307–313.
288. **Mian I, Bradwell A and Olson A (1991) :** "Structure, function and properties of antibody binding sites". *J Mol Biol* 217 (1): 133–51.
289. **Michael G Rossman, (2010) :** Some association exists between hepatitis B infection and PAN : <http://www.britannica.com/EBchecked/topic/623748/vasculitis>
290. **Mierau and Genth (2006) :** Scleroderma associated autoantibodies - clinical and diagnostic relevance. *Z Rheumatol.* Jun 21.
291. **Milland J and Sandrin MS (2006) :** "ABO blood group and related antigens, natural antibodies and transplantation". *Tissue Antigens* 68 (6): 459–66.
292. **Miller C, Ragheb JA, Schwartz RH (1999) :** "Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo". *J. Exp. Med.* July, 190 (1): 53–64.
293. **Miller NW, Bengtén E, Edholm ES, Santini PA, Rath P, Chiu A, Cattalini M, Litzman J, B Bussel J, Huang B, Meini A, Riesbeck K, Cunningham-Rundles C, Plebani A, Cerutti A (2009) :** Immunodeficiency; genetic factor; *Nature Immunology* 10 (8): 889–98.
294. **Millikan LE, Flynn TC and Muckelaman R (2007) :** Infectious etiologies of cutaneous vasculitis. *Clin Dermatol*;17: 509-14.

295. **Miniati I, Guiducci S, Mecacci F, Mello G, Matucci-Cerinic M (2008) :** Pregnancy in systemic sclerosis. *Rheumatology* 47(Suppl 3):iii16–18.
296. **Minoru Satoh, Monica Vázquez-Del Mercado, and Edward K L Chan (2009) :** Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. *Modern Rheumatology*. March 11.
297. **Minskoff S.A, et al., (1998) :** *J. Immunol.* 161:2079.
298. **Mir A, Porteu F, Levy M, et al., (1988) :** C3b receptor (CR1) on phagocytic cells from SLE patients: analysis of the defect and familial study. *Clin Exp Immunol*;73: 461–6.
299. **Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K; Fausto and Nelson (2007) :** *Robbins Basic Pathology*. Philadelphia: Saunders. 8th edition.
300. **Mitchell, Richard Sheppard; Kumar, Vinay; Abbas, Abul K; Fausto; and Nelson Robbins (2007) :** *Basic Pathology*. Philadelphia: Saunders. Hypersensitivity; 8th edition pp:53-65.
301. **Mohammed Mubashir Ahmed, (2010) :** <http://www.britannica.com/EBchecked/topic/331037/vasculitis>
302. **Mok CC and Lau CS (2006) :** Profile of sex hormones in patients with systemic lupus erythematosus. *Lupus*;9: 252–7.
303. **Molina and Shoenfeld (2005) :** "Infection, vaccines and other environmental triggers of autoimmunity". *Autoimmunity*, May;38(3):235-4
304. **Monie TP, Moncrieffe MC, Gay NJ (2009) :** *Immunol Rev* Jan;227(1): 161-75. Structure and regulation of cytoplasmic adapter proteins involved in innate immune signaling.
305. **Moosig F, Lamprecht P, and Gross WL (2008):** Wegener's Granulomatosis: the current view. *Clin Rev Allergy Immunol*. October;35(1-2): 19-21.
306. **Morimoto C, Romain PL, Fox DA, Anderson P, DiMaggio M, Levine H, and Schlossman SF (1988) :** Abnormalities in CD4+ T-

lymphocyte subsets in inflammatory rheumatic diseases. Am J Med, 84: 817-825.

307. **Muhammed Muneer, (2010) :** <http://www.similima.Com> path 11.html
308. **Mukundan Attur, Hayf E. Al-Mussawir, Jyoti Patel, Alison Kitay, Mandar Dave, Glyn Palmer, Michael H. Pillinger and Steven B. Abramson (2008) :** The Journal of Immunology, 181, 5082 -5088.
309. **Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M, Lock RB (2000) :** "Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells". Cell Death Differ. January. 7 (1): 102–11.
310. **Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, Shifrin N, Petri MA, Kamboh MI, Manzi S, Seldin MF, Gregersen PK, Behrens TW, Ma A, Kwok PY, Criswell LA (2008) :** Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet;40:1062–1064.
311. **N. A. Fathi, (2008) :** Antiphospholipid Antibodies (aPL) And Vascular Endothelial Growth Factor In Systemic Lupus Erythematosus, AB0974-AHP. EULAR
312. **N. U. Radoja, Wang, D., M. Hevey, L. Y. Juompan and C. M. Trubey (2006) :** Killer T cells are activated when their receptor (TCR) binds to this specific antigen in a complex with the MHC Class I receptor.J. Immunology, 164: 2619-2628.
313. **Nakamura K, et al., (2001) :** J. Exp. Med. 194:629.
314. **Nathan C, (2002) :** Inflammation: points of control. Nature , 420:846-852.
315. **Nathan C, (2006) :** Neutrophils and immunity: challenges and opportunities. Nature Rev Immunol, 6:173-182.
316. **Nelson JL, Furst DE, Maloney S, et al., (1998) :** Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet Feb 21;351(9102): 559-62.

317. **Nemazee D, (2006) :** "Receptor editing in lymphocyte development and central tolerance". *Nat Rev Immunol* 6 (10): 728–40.
318. **Nicaise Roland P, Grootenboer Mignot S, Bruns A, et al., (2008) :** "Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy". *Arthritis Res. Ther.* 10 (6): R142.
319. **Nicola Bizzaro, (2008) :** The Predictive Significance of Autoantibodies in Organ-Specific Autoimmune Diseases *Clinical Reviews in Allergy and Immunol* Volume 34, Number 3, 326-331.
320. **Nihtyanova SI and Denton CP (2010) :** Autoantibodies as predictive tools in systemic sclerosis. Strong links exist between autoantibody specificities and disease presentation and outcome. *Nat Rev Rheumatol.* 36 (1): 93-103.
321. **Niles JL, Bottinger EP, Saurina GR, et al., (1996) :** The syndrome of lung hemorrhage and nephritis is usually an ANCA associated condition. *Arch Intern Med*;156:440-5.
322. **Nishimoto N, (2010) :** Interleukin-6 as a therapeutic target in candidate inflammatory diseases. *Clin Pharmacol Ther.* Apr ;87 (4): 483-7.
323. **Nishimura K, Sugiyama D, Kogata Y, et al., (2007) :** "Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis". *Annals of Internal Medicine* 146 (11): 797–808.
324. **Nishimura K, Sugiyama D, Kogata Y, et al., (2007) :** "Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis" (PDF). *Ann. Intern. Med.* June, 146 (11): 797–808.
325. **Notarangelo LD, (2010) :** Primary immunodeficiencies. *J Allergy Clin Immunol.* Feb ;125(2 Suppl 2): S182-94.
326. **Ogawa Y and Calhoun WJ (2006) :** "The role of leukotrienes in airway inflammation". *The Journal of Allergy and Clinical Immunology* 118 (4): 789–98; quiz 799–800.
327. **Ohashi, P. (2002) :** illustration has been adapted from *Nat. Rev. Immunol.* 2:427.

328. **Or-Guil M, Wittenbrink N, Weiser AA and Schuchhardt J (2007)** : "Recirculation of germinal center B cells: a multilevel selection strategy for antibody maturation". *Immunol. Rev.* 216: 130–41.
329. **Oshima M, Deitiker P, Ashizawa T, Atassi M (2002)** : "Vaccination with a MHC class II peptide attenuates cellular and humoral responses against tAChR and suppresses clinical EAMG". *Autoimmunity* 35 (3): 183–90.
330. **P. P. Y. Lui, L. s. Chan, S. c. Fu, and K. m. Chan (2010)** : Expression of Sensory Neuropeptides in Tendon Is Associated With Failed Healing and Activity-Related Tendon Pain in Collagenase-Induced Tendon Injury. *Am. J. Sports Med.* 38, 757-764.
331. **P. Wang, F. Zhu, and K. Konstantopoulos (2010)** : *Am J Physiol Cell Physiol*, June 1,298(6): C1445 - C1456.
332. **Pagana KD and Pagana TJ (2006)** : *Mosby's Manual of Diagnostic and Laboratory Tests*, 3rd ed.
333. **Palm NW and Medzhitov R (2009)** : Pattern recognition receptors and control of adaptive immunity. *Immunol Rev.* Jan; 227 (1): 221-33.
334. **Pamela H Kempert, (2010)** : <http://emedicine.medscape.com/article/960027/overview>
335. **Pannu J, Asano Y, Nakerakanti S, et al.,(2008)** : Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. *Arthritis Rheum.* Aug;58(8): 2528-37.
336. **Papiernik M, et al., (1997)** : *Int. Immunol.* 10:371.
337. **Parisi G, (1990)** : "A simple model for the immune network". *Proc. Natl. Acad. Sci. USA* 87: 429-433.
338. **Park MC, Lee SW, Park YB, Chung NS, Lee SK (2005)** : Clinical characteristics and outcomes of Vasculitis of the central nervous system: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. *Scand J Rheumatol.* Jul-Aug;34(4):284-92.
339. **Parker CW, (1975)** : Drug allergy. *N Engl J Med*; 292: 511-4.
340. **Parker D, (1993)** : "T cell-dependent B cell activation". *Annu. Rev. Immunol.* 11: 331–60.

341. **Parks C G, Conrad K, and Cooper G S (1999)** : Environ Health Perspect. October; 107(Suppl5): 793–802. Occupational exposure to crystalline silica and autoimmune disease.
342. **Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J (2005)** : Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med, 201: 1479-1486.
343. **Paul A. Linnemeyer (2008)** : The Immune System -An Overview
Seattle Treatment Education Project <http://wwfw.thebody.com/content/art1788.html>
344. **Perez C, Mendoza H, Hernandez R, Valcayo A, and Guarch R (1997)** : Leukocytoclastic vasculitis and polyarthritis associated with Mycoplasma pneumoniae infection. Clin Infect Dis; 25:154-5.
345. **Peter Parham, (2005)** : "The Immune System. 2nd ed. Garland Science: New York, pg.47-62.
346. **Petty RE and Cassidy JT (2001)** : Juvenile Rheumatoid Arthritis. In Textbook of Pediatric Rheumatology. Edited by: Cassidy JT, Petty RE. Philadelphia: WB Saunders Co;p 262.
347. **Phillip R and Luqmani R (2008)** : Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol. September-October 2008;26:S94-S104.
348. **Piccirillo C and Shevach E.M (2001)** : J. Immunol. 167:1137.
349. **Pichlmair A and Reis e Sousa C (2007)** : innate recognition. Immunity; 27:370-383.
350. **Pier GB, Lyczak JB and Wetzler LM (2004)** : Immunology, Infection, and Immunity. ASM Press.
351. **Pierce and Benjamin A (2010)** : Genetics: A Conceptual Approach. 2nd edition.
352. **Pierce S.K, (2002)** : Nat. Rev. 2:96.
353. **Pierce, S.K. (2002)** : illustration has been adapted from Nat. Rev. 2:96.
354. **Pike B, Boyd A, Nossal G (1982)** : Clonal anergy: the universally anergic B lymphocyte". Proc Natl Acad Sci USA 79 (6): 2013–7.

355. **Pincus T, (2006) :** Advantages and limitations of quantitative measures to assess rheumatoid arthritis - joint counts, radiographs, laboratory tests, and patient. *Bull Hosp Jt Dis.*, 64 (1-2): 32-9.
356. **Pisetsky DS, (1997) :** Systemic lupus erythematosus. A. Epidemiology, pathology and pathogenesis. In: Klippel JH, ed. *Primer on the rheumatic diseases* 11th ed. Georgia, USA: Arthritis Foundation, 246–51.
357. **Plenge RM, Seielstad M, Padyukov L, et al., (2007) :** "TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study". *N. Engl. J. Med.* September 357 (12): 1199–209.
358. **Poole BD, Schneider RI, Guthridge JM, et al., (2009) :** "Early targets of nuclear RNP humoral autoimmunity in human systemic lupus erythematosus". *Arthritis Rheum.* February 60 (3): 848–859.
359. **Popov SG, Villasmil R, Bernardi J (2002) :** "Lethal toxin of *Bacillus anthracis* causes apoptosis of macrophages". *Biochem. Biophys. Res. Commun.* April 293 (1): 349–55.
360. **Pravitt Gourh, (2009):** Plasma cytokine profiles in systemic sclerosis (SSc): associations with autoantibody subsets and clinical manifestations *Arthritis Research and Therapy* Feb12; (7th Space).
361. **Prescott SL, (2009) :** Role of dietary immunomodulatory factors in the development of immune tolerance.;64:185-94; discussion 194-200, 251-7. Aug 19.
362. **Preud'homme JL, Petit I, Barra A, Morel F, Lecron JC and Lelièvre E (2000) :** "Structural and functional properties of membrane and secreted IgD". *Mol. Immunol.* 37 (15): 871–87.
363. **Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, et al., (2002) :** A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. *Nat Genet*;32:666–9.
364. **Putnam FW, Liu YS and Low TL (1979) :** "Primary structure of a human IgA1 immunoglobulin. IV. Streptococcal IgA1 protease, digestion, Fab and Fc fragments, and the complete amino acid sequence of the alpha 1 heavy chain". *J Biol Chem* 254 (8): 2865–74.

365. **Racaniello and Vincent (2009)** : "Natural antibody protects against viral infection". Virology Blog. <http://www.virology.ws/natural-antibody-protects-against-viral-infection>.
366. **Radice A and Sinico RA (2005)** : Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity; 38 (1): 93-103.
367. **Rahman P and Elder JT (2005)** : Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis;64 (suppl II): ii37–9.
368. **Rahman P, Bartlett S, Siannis F, Pellett FJ, Farewell VT, Peddle L, et al., (2006)** : CARD15; a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet;73: 677–81.
369. **Raju TN, (1999)** : "The Nobel chronicles.1972: Gerald M Edelman (b 1929) and Rodney R Porter (1917-85)". Lancet 354 (9183): 1040.
370. **Raptopoulou A, Sidiropoulos P, Katsouraki M, Boumpas DT (2007)** : "Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts". Crit Rev Clin Lab Sci 44 (4): 339–63.
371. **Ravetch J and Bolland S (2001)** : "IgG Fc receptors". Annu Rev Immunol 19: 275–90.
372. **Reece, Jane, Campbell and Neil (2002)** : Biology. San Francisco: Benjamin Cummings. p.907.
373. **Renaudineau Y and Le Meur Y (2008)** : pathogenic mechanism of Renal involvement in Wegener's Granulomatosis. Clinic Rev Allerg Immunol. October (35): 22-29.
374. **Retter M.W and Nemazee D (1998)** : J. Exp. Med. 188:1231.
375. **Reumaux D, Duthilleul P and Roos D (2004)** : Pathogenesis of diseases associated with antineutrophil cytoplasm autoantibodies. Hum Immunol; 65 (1): 1-12.
376. **Reveille JD, (2006)** : The genetic basis of ankylosing spondylitis. Curr Opin Rheumatol 18: 332-341.

377. **Rhen T and Cidlowski JA (2005)** : Antiinflammatory action of glucocorticoids; The immunosuppressive macrolides new mechanisms for old drugs. *N Engl J Med*. Oct 20;353 (16): 1711-23.
378. **Richmond H and Morton R (1948)** : Presentation of two bone marrow components, the tart cell and the LE cell. *Mayo Clin Proc*; 27: 25–28.
379. **Ricklin D and Lambris JD (2007)** : Complement-targeted therapeutics. *Nat Biotechnol*; 25: 1265.
380. **Rider V, Jones S, Evans M, et al., (2004)** : Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. *J Rheumatol* ;28: 2644–9.
381. **Rioux JD and Abbas AK (2005)** : Paths to understanding the genetic basis of autoimmune disease. *Nature* 435: 584–589.
382. **Robert A Schwartz, Bozena Dzikowska-Bartkowiak, Anna Zalewska, Anna Sysa-Jedrzejowska, (2010)** : "Autoimmunogenic aspect of systemic sclerosis;" *J Rheumatol*, May 26.
383. **Rolink A.G. et al., (2001)** : *Curr. Opin. Immunol.* 13:202.
384. **Rolink A.G. et al., (2001)** : *Immunity* 12:619.
385. **Roopa Srinivasan, Alan N. Houghton, and Jedd D. Wolchok (2002)** : Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: Unexpected reactivity to a protein paralogue.
386. **Rose M, (2001)** : Mutation in Ig V-gene and autoimmunity; *J Autoimmun*; 14: 1-10.
387. **Rose HM, Ragan E, Pearce E and Lipman MO (1948)** : "Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis". *Proc Soc Exp Biol Med* 68: 1–11.
388. **Rostaing L, Modesto A, Cisterne JM, Izopet J, Oksman F, Duffaut M, Abbal M and Durand D (1998)** : "Serological markers of

autoimmunity in renal transplant patients with chronic hepatitis C".
American journal of nephrology 18 (1): 50–56.

389. **Roux K, (1999) :** "Immunoglobulin structure and function as revealed by electron microscopy". Int Arch Allergy Immunol 120 (2): 85–99.
390. **Rubtsova K, Kappler JW and Marrack P (2010) :** Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev. May;9 (7): 494-8.
391. **Rus H, Cudrici C and Niculescu F (2005) :** "The role of the complement system in innate immunity". Immunologic Research 33 (2): 103–12.
392. **Ryu J, Treadwell BV, and Mankin HJ (1984) :** Biochemical and metabolic abnormalities in normal and osteoarthritic human articular cartilage. Arthritis Rheum; 27: 49.
393. **S. Leng, J. McElhaney, J. Walston, D. Xie, N. Fedarko and G. Kuchel (2008) :** "Elisa and Multiplex Technologies for Cytokine Measurement in Inflammation and Aging Research". J Gerontol A Biol Sci Med Sci October 63: 879–884.
394. **Saccardi R, Kozak T, Bocelli-Tyndall C, Fassas A, Kazis A, Havrdova E, Carreras E, Saiz A, Lwenberg B, Boekhorst PA, Gualandio F, Openshaw H, Longo G, Pagliai F, Massacesi L, Deconink E, Ouyang J, Nagore FJ, Besalduch J, Lisukov IA, Bonini A, Merelli E, Slavino S, Gratwohl A, Passweg J, Tyndall A, Steck AJ, Andolina M, Capobianco M, Martin JL, et al., (2008) :** SSc and the different types of vasculitis Mult Scler , 12: 814-823.
395. **Sakkas LI, (2005) :** New developments in the pathogenesis of systemic sclerosis. Autoimmunity. Mar;38(2): 113-6.
396. **Salmon M and Gordon C (1999) :** The role of apoptosis in systemic lupus erythematosus. Rheumatology (Oxford); 38:1177–83.
397. **Samejima K, Tone S, Kottke TJ, Enari M, Sakahira H, Cooke CA et al., (1998) :** Transition from caspase-dependent to caspase-independent mechanisms at the onset of apoptotic execution. J Biol Chem;143: 225–39.

398. **Samuelsson L, Enlund F, Torinsson A, Yhr M, Inerot A, Enerback C, et al., (1999) :** A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach. *Hum Genet*; 105:523–9.
399. **Sansom D.M, (2000) :** *Immunology* 101:169.
400. **Sansonno D and Dammacco F (2005) :** Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. *Lancet Infect Dis. Apr* ;5(4):227-36.
401. **Saunders K, Raine T, and Lawrence C (2007) :** "Localized autoimmune diseases *Infect Immun* 75 (3): 397–407.
402. **Saunders K, Raine T, Cooke A and Lawrence C (2007) :** "Inhibition of autoimmune type 1 diabetes by gastrointestinal helminth infection". *Infect Immun* 75 (1): 397–407.
403. **Savage COS, Harper L, and Adu D (1997) :** Primary systemic vasculitis. *Lancet*;349:553-7.
404. **Savill J, (1997) :** Recognition and phagocytosis of cells undergoing apoptosis. *Br Med Bull*; 53: 491–508
405. **Savino W et al., (2002) :** *Trends Immunol.* 23: 305.
406. **Scapini P, Carletto A, Nardelli B, Calzetti F, Roschke V, Merigo F, Tamassia N, Pieropan S, Biasi D, Sbarbati A, Sozzani S, Bambara L, Cassatella MA (2005) :** Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. *Blood*, 105: 830-837.
407. **Schmidt WA and Blockmans D (2005) :** Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. *Curr Opin Rheumatol. Jan* ;17(1): 9-15.
408. **Schur PH, (1995) :** Genetics of systemic lupus erythematosus. *Lupus*; 4: 425–37.

409. **Schwarz BA and Bhandoola A (2006)** : Trafficking from the bone marrow to the thymus: a prerequisite for thymopoiesis. *Immunol Rev* 209:47.
410. **Scott DGI, Bacon E, and Elliot PJ (1982)** : Systemic vasculitis in a district general hospital 1972-1980: Clinical and laboratory features, classification and prognosis in 80 cases. *Q J Med*; 203: 292-311.
411. **Sebbag M, Simon M, Vincent C, Masson-Bessière C, Girbal E, Durieux JJ and et al., (1995)** : The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. *J Clin Invest.* 95: 2672–9.
412. **Semana G et al., (1999)** : *J. Autoimmun.* 12: 259.
413. **Seo P and Stone J (2004)** : The Antineutrophil Cytoplasmic Antibody-Associated Vasculitides. *Am J Med*; 117: 39-50.
414. **Sergio Generini, (2009)** : Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement; *Rheumatology Advanced Access*. May 29.
415. **Sharpe A.H. and Freeman G.J. (2002)** : *Nat. Rev. Immunol.* 2:116.
416. **Shaun Ruddy, Bennett R.M, Edward D, Harris Jr, Clement B, Sledge, Gary S. Firestein, John S. Sergent, Mark C. Genovese and Ralph C., Budd W. B. (2007)** : "Autoantibodies are present in low titers in the general population "in *Textbook of Rheumatology*, 8 th Edition, EditorsSaunders Co., Philadelphia.
417. **Shenman and Douglas H (2006)** : Evolution and the Spiral of Technology. Trafford Publishing. <http://en.wikipedia.org/wiki/HLA>
418. **Shepherd B et al., (2005)** : "Inflammatory Bowel Disease: Diagnostic and Treatment Options". *Hospital Physician*: 11–19.
419. **Sherwood L, (2010)** : *Human physiology; from cells to systems*. 7th ed. Australia ; United States: Cole Cengage Learning;
420. **Shevach E.M, (2002)** : *Nat. Rev. Immunol.* 2:389.
421. **Shihoko Okazaki, (2009)** : "Autoantibody (Ab) against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis (SSc)" (Springer Link) *Rheumatology International*. July 28.

422. **Shiloh MU, MacMicking JD, Nicholson S, Brause JE, Potter S, Marino M, Fang F, Dinanuer M, Martinon F, Pétrilli V, Mayor A, Tardivel A and Tschopp J. (2006) :** Innate recognition to differentiate between self and non-self *Ann. Rev*;118 (4): 789–98.
423. **Shin YS, Choi JH, Nahm DH, et al., (2005) :** Rheumatoid factor is a marker of disease severity in Korean rheumatoid arthritis. *Yonsei Med J.* Aug 31;46 (4): 464-70.
424. **Shinkai Y, et al., (1993) :** *Science* 259:822.
425. **Shoenfeld Y and Aron-Maor A (2000) :** "Vaccination and autoimmunity - Vaccinosis: A dangerous liaison?" *J Autoimmun*; 14: 1-10.
426. **Silverstein AM, (2003) :** "Cellular versus humoral immunology : a century-long dispute". *Nat. Immunol.* 4 (5): 425–8.
427. **Silverstein AM, (2004) :** "Labeled antigens and antibodies: the evolution of magic markers and magic bullets". *Nat. Immunol.* 5 (12): 1211–7.
428. **Sim RB and Tsiftoglou SA (2004) :** "Proteases of the complement system". *Biochemical Society Transactions* 32 (Pt 1): 21–7.
429. **SL Nihtyanova, (2010) :** Autoantibodies as predictive tools in systemic sclerosis; *Nat Rev Rheumatol.* Feb.
430. **Smith JA, Märker-Hermann E, Colbert RA (2006) :** Pathogenesis of ankylosing spondylitis; current concepts. *Best Pract Res Clin Rheumatol* 20: 571-591.
431. **Sokol C.L., Barton G.M., Farr A.G. and Medzhitov R. (2008) :** "A mechanism for the initiation of allergen-induced T helper type 2 responses". *Nat Immunol* 9 (3): 310–318.
432. **Soler-Palacn P, Margareto C, Llobet P, et al., (2007) :** "Chronic granulomatous disease in pediatric patients: 25 years of experience". *Allergol Immunopathol (Madr)* 35 (3): 83–9.
433. **Spencer-Green G, Alter D, Welch HG (1997) :** Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies. *Am J Med.* Sep;103(3): 242-8.
434. **Sperling A.I. et al., (1996) :** *J. Immunol.* 157: 3909.

435. **Sridhar Rao PN, (2006) :** www.microrao.com
436. **Sriskandan S, Faulkner L and Hopkins P (2007) :** Streptococcus pyogenes: Insight into the function of the streptococcal superantigens". Int. J. Biochem. Cell Biol. 39 (1): 12–9.
437. **Stacy P Ardoin and David S Pisetsky (2008) :** Developments in the scientific understanding of lupus Arthritis Research and Therapy, 10:218.
438. **Stauffer Y, Marguerat S, Meylan F, et al., (2001) :** "Interferon-alpha-induced endogenous superantigen. a model linking environment and autoimm- unity". Immunity October, 15 (4): 591–601.
439. **Stavnezer J and Amemiya CT (2004) :** "Evolution of isotype switching". Semin. Immunol. 16 (4): 257–75.
440. **Stefanova I., Dorfman J. R. and Germain R. N. (2002) :** autoimmune disorder; " failure of self-recognition promotes the sensitivity of naive T lymphocytes". Nature 420 (6914): 429–434.
441. **Steinman R.M. and M.C. Nussensweig (2002) :** Proc. Natl. Acad. Sci. USA 99:351.
442. **Steven GE Marsh, (2010) :** hla.alleles.org
443. **Stevens FJ, Solomon A and Schiffer M (1991) :** "Bence Jones proteins: a powerful tool for the fundamental study of protein chemistry and pathophysiology". Biochemistry 30 (28): 6803–5.
444. **Stiles BG and Krakauer (2005) :** "Staphylococcal Enterotoxins: a Purging Experience in Review, Part I". Clinical Microbiology Newsletter 27: 23.
445. **Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, Kumagai S (2010) :** "Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies". Ann Rheum Dis. Jan 69 (1): 70–81.
446. **Susan D Moffatt-Bruce, (2008) :** Induction of Tolerance <http://emedicine.medscape.com/article/430449/overview>
447. **Susin SA, Lorenzo HK, Zamzami N (1999) :** "Molecular characterization of mitochondrial apoptosis-inducing factor". Nature February; 397 (6718): 441–6.

448. **Syngle A, Vohra K, Sharma A, Kaur L. (2010)** : Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade. *Clin Rheumatol*. Jul;29(7):763-70. Mar 5.
449. **Syuto T, Shimizu A, Takeuchi Y, et al., (2009)** : "Association of antiphosphatidylserine/prothrombin antibodies with neuropsychiatric systemic lupus erythematosus and lupus nephritis" *Clin. Rheumatol*. February 28 (7): 841–5.
450. **Tai YJ, Chong AH, Williams RA, Cumming S, Kelly RI. (2006)** : Retrospective analysis of adult patients with cutaneous leukocytoclastic vasculitis. *Australas J Dermatol*. May ;47(2): 92-6.
451. **Takahashi T. et al., (2000)** : *J. Exp. Med.* 192:303.
452. **Tannock IF and Hill RP et al., (2005)** : *The Basic Science of Oncology* 4th ed. McGraw-Hill.
453. **Terrier B, (2008)** : *American Journal of Respiratory and Critical Care Medicine* Vol 177. pp. 1128-1134,.
454. **Terrier B, Saadoun D, Sène D, Ghillani P, Amoura Z, Deray G, et al., (2009)** : useful markers of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. *Ann Rheum Dis*. Oct; 68(10) : 1564-71.
455. **Tervaert JWC, Popa ER and Bos NA (1999)** : The role of superantigens in vasculitis. *Curr Op Rheum*;11: 24-33.
456. **Thompson C.B. and Shevach E.M. et al., (2003)** : *Proc. Natl. Acad. Sci. USA* 86:1333.
457. **Tian B, Nowak DE and Brasier AR. (2005)** : A TNF-induced gene expression program under oscillatory NF-kappaB control. *BMC Genomics*. Sep 28;6:137.
458. **Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, et al., (2003)** : An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. *Nat Genet*; 35: 341–8.

459. **Tolar P, Sohn HW and Pierce SK (2008)** : "Viewing the antigen-induced initiation of B-cell activation in living cells". *Immunol. Rev.* 221: 64–76.
460. **Tomasi TB, (1992)** : "The discovery of secretory IgA and the mucosal immune system". *Immunol. Today* 13 (10): 416–8.
461. **Torsteinsdottir I, Arvidson NG, Hallgren R, Hakansson L (1999)** : Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils patients with rheumatoid arthritis, and the effect of glucocorticoids. *Scand J Immunol* , 50:433-439.
462. **Townes JM, Deodhar AA, Laine ES, et al., (2008)** : Reactive arthritis following culture-confirmed infections with bacterial genitourinary or enteric pathogens in Minnesota and Oregon: a population-based study. *Ann Rheum Dis.* Dec;67(12): 1689-96.
463. **Travis MA et al., (2007)** : Loss of integrin alpha (v)beta8 on dendritic cells causes autoimmunity and colitis in mice. *Nature.* Sep 20;449(7160):361-5. Aug 12.
464. **Trung PH, Prieur AM, and Griscelli C (1980)** : Neutrophil chemotaxis in juvenile chronic arthritis. *Ann Rheum Dis* , 39: 481-484.
465. **Uz E, Loubiere LS, Gadi VK, et al., (2008)** : Skewed X-chromosome inactivation in scleroderma". *Clin Rev Allergy Immunol*, June 34 (3): 352–5.
466. **V. Geraci SA, (2007)** : "Rheumatoid arthritis: diagnosis and management". *Am. J. Med.* 120 (11): 936–9.
467. **Van der Woude FJ, Rasmussen N, Lobatto S et al., (1985)** : Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. *Lancet*; 1 (8426): 425-9.
468. **Van Epps HL, (2006)** : "Michael Heidelberger and the demystification of antibodies". *J. Exp. Med.* 203 (1): 5.

469. **Van Gaalen F, Ioan-Facsinay A, Huizinga TW, and Toes RE (2005) :** "The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis". *J. Immunol.* 175 (9): 5575–80.
470. **Van Nieuwenhuijze, A.E., T. van Lopik, R.J. Smeenk, and L.A. Aarden (2003) :** Time between onset of apoptosis and release of nucleosomes from apoptotic cells: putative implications for systemic lupus erythematosus. *Ann. Rheum. Dis.* 62:10–14.
471. **Vance R.E, (2000) :** Cutting edge commentary: A Copernican Revolution? Doubts about the danger theory. *Journal of Immunology* 165:1725-1728.
472. **Vandal OH, Pierini LM, Schnappinger D, Nathan CF, and Ehrt S (2008) :** "phagosome subsequently fuses with lysosome to form a phagolysosome". *Nat Med.* 14 (8): 849–854.
473. **Vedove CD, Del Giglio M, Schena D and Girolomoni G (2009):** Autoantibodies and Drug-induced lupus erythematosus. *Arch Dermatol Res.* Jan; 301(1): 99-105.
474. **Vereecke L, Beyaert R, van Loo G. (2009) :** The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology *Trends Immunol.* Aug;30 (8): 383-91. Epub Jul 28. Review.
475. **Verrecchia F, Laboureaux J, Verola O, et al., (2007) :** Skin involvement in scleroderma-where histological and clinical scores meet. *Rheumatology (Oxford).* May ;46(5): 833-41.
476. **Victor FC and Gottlieb AB (2002) :** TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. *J Drugs Dermatol*; 1:264–75.
477. **Vilma Urbonaviciute, Barbara G. Fürnrohr, Silke Meister, Luis Munoz, Petra Heyder, Francesco De Marchis, Marco E. Bianchi, Carsten Kirschning, Hermann Wagner, Angelo A. Manfredi, Joachim R. Kalden, Georg Schett,Patrizia Rovere-Querini, Martin Herrmann, and Reinhard E. Voll (2008) :** Induction of inflammatory and immune responses by HMGB1–nucleosome

complexes: implications for the pathogenesis of SLE Dec. 8, JEM vol. 205no. 133007-3018.

- 478. **Vittecoq O, Pouplin S, Krzanowska K, et al., (2003)** : Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. *Rheumatology (Oxford)* Aug; 42 (8): 939-46.
- 479. **Vojdani A, (2008)** : Antibodies as predictors of complex autoimmune diseases. *Int J Immunopathol Pharmacol*. Jun; 21 (2): 267-78.
- 480. **Wajant H (2002)** : "The Fas signaling pathway: more than a paradigm". *Science* 296 (5573): 1635–6.
- 481. **Wajant, H. (2009)** : "Connection Map for Fas Signaling Pathway". *Science*. http://stke.sciencemag.org/cgi/cm/CMP_7966.
- 482. **Walker L.S.K. and A.K. Abbas (2002)** : *Nat. Rev. Immunol.* 2:11.
- 483. **Walker, L.S.K. and A.K. Abbas (2002)** : illustration has been adapted from *Nat. Rev. Immunol.* 2:11
- 484. **Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA et al., (2008)** : The diagnosis and management of rhinitis: an updated practice parameter. *J Allergy Clin Immunol*. Aug; 122(2).
- 485. **Walport MJ, Davies KA, and Botto M (2007)** : C1q and systemic lupus Erythematosus; *Nat. Immunol.*6: 487–496.
- 486. **Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al., (2007)** : Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Ann Rheum Dis*. Feb;66(2): 222-7.
- 487. **Weinman EJ, (2001)** : New functions for the NHERF family of proteins. *J Clin Invest*;108: 185–6.
- 488. **Weintraub R.C. et al., (2000)** : *J. Exp. Med.* 191:1443.
- 489. **Wilson D, (2006)** : Rheumatoid factors in patients with rheumatoid arthritis. *Can Fam Physician*. Feb; 52: 180-1.

490. **Wintrobe and Maxwell Myer (2004)** : Wintrobe's clinical hematology. John G. Greer, John Foerster, John N Lukens, George M Rodgers, Frixos Paraskevas (11 ed.). Hagerstown, MD: Lippincott Williams & Wilkins. pp. 453–456.
491. **Wisnieski JJ, (2000)** : Urticarial vasculitis. *Curr Op Rheum*; 12: 24-31.
492. **Witort-Serraglini E, Del Rosso M, Lotti TM, et al., (1999):** Endothelial injuries in vasculitides. *Clin in Derm*;17:587-90.
493. **Wochenschr, (2008)** : Autoantibodies in systemic sclerosis (scleroderma); clues for clinical evaluation, prognosis and pathogenesis. *Wien Med Wochenschr*. Jan;158(1-2):19-28.
494. **Woof J and Burton D (2004)** : "Human antibody-Fc receptor interactions illuminated by crystal structures". *Nat Rev Immunol* 4 (2): 89–99.
495. **Wu IB and Schwartz RA (2008)** : Reiter's syndrome: the classic triad and more. *J Am Acad Dermatol*. Jul ;59(1):113-21.
496. **Yamaguchi A, Tsuchiya N, Mitsui H, Shiota M, Ogawa A, Tokunaga K, et al., (1995)** : Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. *Arthritis Rheum* 38:1672-1677.
497. **Yamaguchi M, Nadler S, Lee JW, Deeg HJ (1999)** : "Induction of negative regulators of haematopoiesis in human bone marrow cells by HLA-DR cross-linking". *Transpl. Immunol*. September 7 (3): 159–68.
498. **Yang Xiang, Taichi Sekine , Hiroshi Nakamura, Shinobu Imajoh-Ohmi, Hiroyuki Fukuda, Kazuo Yudoh, Kayo Masuko-Hongo, Kusuki Nishioka and Tomohiro Kato (2006)** : *The Journal of Immunology*, 176: 3196-3204.

499. **Yasuhiko Hirabayashi, Yumiko Oka, Tomoko Ikeda, Hiroshi Fujii, Tomonori Ishii, Takeshi Sasaki, and Hideo Harigae (2010) :** The Journal of Immunology, 184, 3276 -3283.
500. **Yoshida H, Pommier Y, and Ueda T (2006) :** Endonuclease activation and chromosomal DNA fragmentation during apoptosis in leukemia cells. Int. J. Hematol. 84:367–376.
501. **Young BJ, Mallya RK, Leslie RD, Clark CJ and Hamblin TJ (1979) :** "Anti-keratin antibodies in rheumatoid arthritis". Br Med J 2 (6182): 97–9.
502. **Zaccone P, Fehervari Z, Phillips JM, Dunne DW and Cooke A (2006) :** Parasitic worms and inflammatory diseases". Parasite Immunol. 28 (10): 515–23.
503. **Zen K and Parkos CA (2003) :** "Leukocyte - epithelial interactions". Current Opinion in Cell Biology 15 (5): 557–64.
504. **Zimmermann-Gorsk (2008):** Polymyalgia rheumatica: clinical picture and principles of treatment. Pol Arch Med Wewn.; 118: 377-380.
505. **Zuber JP and Spertini F (2006) :** Rheumatology, Immunological basis of systemic sclerosis; Volume 45, Supplement 1, October, pp. iii23-iii25(3).